As previously reported, BofA analyst Alec Stranahan upgraded Vir Biotechnology (VIR) to Buy from Neutral with a price target of $14, up from $12, arguing that the market is underestimating the potential for its asset for treatment of severe liver disease caused by hepatitis delta virus. There also seems to be minimal value attributed to T-cell engager oncology programs, despite initial proof-of-concept data, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology upgraded to Buy from Neutral at BofA
- Vir Biotechnology’s Strategic Advancements and Strong Pipeline Drive Buy Rating
- Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating
- Vir Biotechnology’s Earnings Call Highlights Progress and Challenges
- Vir Biotechnology’s Strong Clinical Pipeline and Financial Position Reinforce Buy Rating